Innova Captab
Innova Captab Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Innova Captab Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Innova Captab Ltd trades at a P/E of 38.28× and P/B of 4.94×.
Valuation
Profitability
Growth
Financial Health
Innova Captab Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Innova Captab Ltd, switchable between annual and quarterly views, consolidated or standalone.
Innova Captab Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹5,407.76 Cr and reported EPS of ₹24.62.
| Period | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue from Operations | 1,081 | 1,244 | 1,630 |
| Other Income | 12 | 12 | 7 |
| Total Income | 1,094 | 1,256 | 1,637 |
| Cost of Goods Sold (COGS) | 728 | 814 | 1,053 |
| Gross Profit | 353 | 430 | 577 |
| +Operating Expenses | 199 | 243 | 334 |
| EBITDA | 154 | 186 | 243 |
| +Non-Operating Expenses | 37 | 27 | 62 |
| Profit Before Tax (PBT) | 130 | 171 | 188 |
| +Tax Expense | 35 | 43 | 47 |
| Profit After Tax (PAT) | 94 | 128 | 141 |
| Earnings Per Share (EPS) | 16.49 | 22.41 | 24.63 |
| Diluted Shares Outstanding (Nos.) | 6 | 6 | 6 |
| +Additional Disclosures | 1,694 | 1,899 | 2,502 |
| Sales Growth % | — | 15.02 | 31.06 |
| YoY Sales Growth % | — | 15.02 | 31.06 |
| Material Cost % | 64 | 64 | 62 |
| Employee Cost % | 8 | 9 | 10 |
| Other Cost % | 10 | 10 | 10 |
| OPM % | 14 | 15 | 15 |
| Tax % | 27 | 25 | 25 |
| Profit Growth % | — | 35.95 | 9.87 |
| Gross Margin % | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 |
| Additional Fields | 138 | 161 | 198 |
Innova Captab segment analysis: revenue and profit mix.
Disclosed business segments at Innova Captab with their share of revenue and profit, switchable between consolidated and standalone reporting.
Innova Captab discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Innova Captab Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Innova Captab Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Innova Captab Ltd's investment case rests on 7 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Innova Captab Ltd exhibits consistent profitability with a Return on Equity (ROE) of 14.3% and a healthy Operating Profit Margin (OPM) of 15.1%, indicating efficient operations and strong earnings generation.
The company shows promising growth, with quarterly sales increasing by 19.5%. This upward trend suggests a strong market demand for its products and potential for future revenue expansion.
Despite recent stock price volatility, Innova Captab maintains a relatively stable promoter holding of 50.9%, suggesting confidence in the company's long-term prospects and mitigating some investor concerns.
Innova Captab's Return on Capital Employed (ROCE) stands at 14.6%, demonstrating efficient utilization of capital and a strong competitive advantage within the Pharmaceuticals industry.
The company operates in the "Pharmaceuticals" sector, which is generally a growing industry, driven by increasing healthcare demand and innovation, offering potential for sustained revenue expansion.
What can break it.
Innova Captab Ltd has a relatively high Price-to-Earnings (P/E) ratio of 36.00, potentially indicating the stock is overvalued compared to its earnings. Investors should carefully assess the valuation.
The relatively low dividend yield of 0.00% might be a concern for income-seeking investors. This could limit the appeal to investors prioritizing regular dividend income from their investments.
Recent stock price movements show volatility, with significant daily fluctuations. The stock has seen a 52-week high of 1260 and a low of 662, indicating potential risk for stable returns.
FII holding has significantly decreased from 3.57% in Dec 2023 to 0.08% in Sep 2025, which could signal reduced foreign institutional investor confidence in the company's future prospects.
Innova Captab faces intense competition from larger, well-established players in the Pharmaceuticals sector, such as Sun Pharma and Cipla, which could limit its market share and pricing power.
What would change my mind.
Trim if P/E re-rates above 50. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 32.01. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 9%. The operating engine is no longer compounding capital efficiently.
Innova Captab Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Innova Captab Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Innova Captab Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Innova Captab Ltd — derived from the live tape, not yesterday's close.
Innova Captab Ltd last traded at ₹942.45 with an intraday range of ₹936.6–₹974 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹942.45| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1040.23 | +97.78 | +10.38% |
| R3 | 1002.83 | +60.38 | +6.41% |
| R2 | 988.42 | +45.97 | +4.88% |
| R1 | 965.43 | +22.98 | +2.44% |
| PIVOT | 951.02 | 8.57 | 0.91% |
| CURRENT | 942.45 | — | — |
| S1 | 853.23 | -89.22 | -9.47% |
| S2 | 890.63 | -51.82 | -5.50% |
| S3 | 913.62 | -28.83 | -3.06% |
| S4 | 928.03 | -14.42 | -1.53% |
INNOVACAP is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 950.75 ~ 974
Trading Inside opening range
Innova Captab Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Innova Captab Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Innova Captab Ltd stood at 46.4% of traded volume, against a 20-day average of 48.3%.
Innova Captab announcements: results, concalls, ratings, M&A.
Filings Innova Captab sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Innova Captab files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 98 documents below.
Copy of Newspaper Publication
Innova Captab Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
Innova Captab Limited has informed the Exchange about General Updates in respect of reconstitution of audit committee
Analysts/Institutional Investor Meet/Con. Call Updates
Innova Captab Limited has informed the Exchange about Schedule of meet
Credit Rating
Innova Captab Limited has informed the Exchange about Credit Rating
Updates
Innova Captab Limited has informed the Exchange regarding 'Intimation under Regulation 30
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Innova Captab insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Innova Captab as reported to SEBI — buying and selling signals from the people who know the business best.
Innova Captab insider activity below tracks 3 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Archit Aggarwal | Insider | 24 Mar 2026 | buy | +43.75 L | ₹302.31 Cr | ₹691.00 |
| Archit Aggarwal | Insider | 24 Mar 2026 | buy | +43.75 L | ₹302.31 Cr | ₹691.00 |
| Archit Aggarwal | Insider | 24 Mar 2026 | buy | +43.75 L | ₹302.31 Cr | ₹691.00 |
Innova Captab dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Innova Captab has declared, sequenced by announce and record date.
Innova Captab corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Innova Captab Ltd: business, sector, key facts.
What Innova Captab Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Innova Captab Ltd operates in the Healthcare, listed as NSE: INNOVACAP, BSE: 544067.
Innova Captab Limited is an integrated pharmaceutical company operating in India and internationally. Its core business encompasses the entire pharmaceutical value chain, from research and development to marketing and distribution of its own products and those of other companies. This vertical integration allows for greater control over quality and efficiency throughout the process.
A significant portion of Innova Captab's business involves contract development and manufacturing organization (CDMO) services. The company provides these services to other Indian pharmaceutical firms, leveraging its manufacturing capabilities and expertise to produce drugs according to their specifications. This aspect of the business generates revenue streams independent of the company's own branded products.
Innova Captab manufactures and distributes a wide range of generic formulation products covering numerous therapeutic areas. These include but are not limited to antibiotics (cephalosporins, fluoroquinolones, macrolides), cardiovascular drugs, analgesics, anti-inflammatory agents, antidiabetic medications, and treatments for various other conditions. The company produces these drugs in diverse forms, including tablets, capsules, syrups, injections, and ointments, showcasing its versatility in pharmaceutical manufacturing.
The company's branded generic products reach the market through a multi-channel distribution strategy. This includes a traditional network of distributors and pharmacies, as well as a growing online presence via e-commerce pharmacy websites. This diversified approach allows Innova Captab to access a broader customer base and enhance market reach.
In summary, Innova Captab Limited operates a multifaceted pharmaceutical business model. It combines CDMO services for other pharmaceutical companies with the development, manufacture, and distribution of its own portfolio of branded generic drugs, achieving market access via both traditional and online channels. This integrated approach positions the company strategically within the competitive Indian and international pharmaceutical markets.
Questions investors ask about Innova Captab Ltd (INNOVACAP).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Innova Captab Ltd (INNOVACAP)?
The current share price of Innova Captab Ltd (INNOVACAP) is ₹942.45. Today, the stock has declined by ₹8.30 (0.87%), trading in a range of ₹936.6 to ₹974. The stock opened at ₹964.75 with a trading volume of 1,27,569 shares.
02Is Innova Captab Ltd stock a good investment for long-term?
Innova Captab Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,407.76 crores, P/E ratio of 38.28, ROE of 13.75%, and ROCE of 14.60%. The dividend yield stands at 0.42%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Innova Captab Ltd stock?
The 52-week high price of Innova Captab Ltd (INNOVACAP) is ₹0, while the 52-week low is ₹0. Currently trading at ₹942.45, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Innova Captab Ltd stock at the current price?
Whether to buy Innova Captab Ltd stock at ₹942.45 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.28 and P/B ratio of 4.94. Today's performance shows a loss of 0.87%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Innova Captab Ltd and when is the next dividend?
Innova Captab Ltd offers a dividend yield of 0.42%, which means for every ₹100 invested at the current price of ₹942.45, you can expect to receive approximately ₹0.42 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Innova Captab Ltd?
Innova Captab Ltd's key financial metrics include: P/E Ratio: 38.28, P/B Ratio: 4.94, ROE: 13.75%, ROCE: 14.60%, Dividend Yield: 0.42%, EPS: ₹24.62, Book Value: ₹190.62, and Debt-to-Equity: 31.51. The company's market cap stands at ₹5,407.76 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Innova Captab Ltd stock performing today in the market?
Innova Captab Ltd stock opened at ₹964.75 and is currently trading at ₹942.45, showing a decline of ₹8.30 (0.87%). The intraday high is ₹974 and low is ₹936.6. The trading volume stands at 1,27,569 shares, indicating moderate market participation today.
08What is the P/E ratio of Innova Captab Ltd and what does it indicate?
Innova Captab Ltd has a Price-to-Earnings (P/E) ratio of 38.28, which means investors are willing to pay ₹38.28 for every ₹1 of earnings. With an EPS of ₹24.62, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Innova Captab Ltd (INNOVACAP) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy